Our Offerings
Our Offerings
Accelerate scientific breakthrough, together
Accelerate scientific breakthrough, together
Driven by a passion to advance next-generation therapies, we’ve developed tools that fuel our own work every day.
Now, by making these technologies accessible, we empower scientists worldwide to accelerate discovery and create seismic impact.
Explore our off-the-shelf reagents, custom services, and out-licensing opportunities, and join a movement shaping the future of medicine.
Driven by a passion to advance next-generation therapies, we’ve developed tools that fuel our own work every day.
Now, by making these technologies accessible, we empower scientists worldwide to accelerate discovery and create seismic impact.
Explore our off-the-shelf reagents, custom services, and out-licensing opportunities, and join a movement shaping the future of medicine.
Driven by a passion to advance next-generation therapies, we’ve developed tools that fuel our own work every day.
Now, by making these technologies accessible, we empower scientists worldwide to accelerate discovery and create seismic impact.
Explore our off-the-shelf reagents, custom services, and out-licensing opportunities, and join a movement shaping the future of medicine.
1
iPSC-Derived Cells
Transforming Disease Research with Human-Relevant Models
LumiSTAR's iPSC-derived cells provide researchers and pharmaceutical companies with human-relevant disease models that overcome the limitations of traditional animal testing. Our iPSC platform generates unlimited quantities of differentiated cells with consistent quality. These models enable more accurate prediction of human responses compared to animal models, significantly improving the success rate of drug development programs.
Key applications
• Drug discovery and screening using human disease models
• Cardiotoxicity evaluation with iPSC-derived cardiomyocytes
• Precision medicine through patient-specific cell lines
• Cell therapy development for neurodegenerative and kidney diseases
1
iPSC-Derived Cells
Transforming Disease Research with Human-Relevant Models
LumiSTAR's iPSC-derived cells provide researchers and pharmaceutical companies with human-relevant disease models that overcome the limitations of traditional animal testing. Our iPSC platform generates unlimited quantities of differentiated cells with consistent quality. These models enable more accurate prediction of human responses compared to animal models, significantly improving the success rate of drug development programs.
Key applications
• Drug discovery and screening using human disease models
• Cardiotoxicity evaluation with iPSC-derived cardiomyocytes
• Precision medicine through patient-specific cell lines
• Cell therapy development for neurodegenerative and kidney diseases
1
iPSC-Derived Cells
Transforming Disease Research with Human-Relevant Models
LumiSTAR's iPSC-derived cells provide researchers and pharmaceutical companies with human-relevant disease models that overcome the limitations of traditional animal testing. Our iPSC platform generates unlimited quantities of differentiated cells with consistent quality. These models enable more accurate prediction of human responses compared to animal models, significantly improving the success rate of drug development programs.
Key applications
• Drug discovery and screening using human disease models
• Cardiotoxicity evaluation with iPSC-derived cardiomyocytes
• Precision medicine through patient-specific cell lines
• Cell therapy development for neurodegenerative and kidney diseases
2
LumiRDT® Biosensors
Next-Generation Real-time Detection Technology
LumiRDT® represents LumiSTAR's genetically encoded biosensor platform that enables real-time cellular analysis through protein-based indicators. Unlike chemical fluorescent dyes that suffer from photobleaching and cellular toxicity, LumiRDT® are stably expressed in the cells, enabling continuous monitoring of cellular dynamics (weeks vs. hours for conventional probes), offering superior performance over traditional chemical dyes.
Key Advantages
• Non-toxic to cells enabling long-term observations
• Flexible fluorescence options for multiplexed measurements
• Customizable targeting to specific cellular compartments
• Detecting various cellular parameters, such as calcium transient and ROS levels
2
LumiRDT® Biosensors
Next-Generation Real-time Detection Technology
LumiRDT® represents LumiSTAR's genetically encoded biosensor platform that enables real-time cellular analysis through protein-based indicators. Unlike chemical fluorescent dyes that suffer from photobleaching and cellular toxicity, LumiRDT® are stably expressed in the cells, enabling continuous monitoring of cellular dynamics (weeks vs. hours for conventional probes), offering superior performance over traditional chemical dyes.
Key Advantages
• Non-toxic to cells enabling long-term observations
• Flexible fluorescence options for multiplexed measurements
• Customizable targeting to specific cellular compartments
• Detecting various cellular parameters, such as calcium transient and ROS levels
2
LumiRDT® Biosensors
Next-Generation Real-time Detection Technology
LumiRDT® represents LumiSTAR's genetically encoded biosensor platform that enables real-time cellular analysis through protein-based indicators. Unlike chemical fluorescent dyes that suffer from photobleaching and cellular toxicity, LumiRDT® are stably expressed in the cells, enabling continuous monitoring of cellular dynamics (weeks vs. hours for conventional probes), offering superior performance over traditional chemical dyes.
Key Advantages
• Non-toxic to cells enabling long-term observations
• Flexible fluorescence options for multiplexed measurements
• Customizable targeting to specific cellular compartments
• Detecting various cellular parameters, such as calcium transient and ROS levels
3
Contracted Services
Let Us Do the Heavy Lifting for You
LumiSTAR offers end-to-end contract research services that combine our technology platform with extensive expertise in phenotypic drug discovery and toxicity evaluation. Our services are designed to accelerate your research and development programs while reducing costs and risks associated with in-house development.
Benefits
• Reduced development timelines through proven methodologies
• Access to specialized expertise and cutting-edge technology
• Cost-effective solutions compared to in-house development
• Regulatory compliance and quality assurance
Available Services
• High-Throughput Screening: Our all-optical platform performs library screening or drug repurposing using various phenotypic and functional assays for different disease modeling, with customization services available to meet your specific needs.
• iPSC Disease Modeling: Comprehensive disease model development and validation using our proprietary iPSC lines. Services include model characterization, biomarker identification, and assay development.
• Cardiotoxicity Testing: Specialized cardiac safety evaluation using human iPSC-derived cardiomyocytes combined with our LumiRDT technology for real-time monitoring of cardiac function and drug-induced toxicity.
• Neurotoxicity Testing: Advanced CNS safety evaluation leveraging human iPSC-derived neuron monocultures or neuron/astrocyte/microglia co-cultures, enabling comprehensive functional assessments of synaptic activity, neuronal viability, and glial responses.
3
Contracted Services
Let Us Do the Heavy Lifting for You
LumiSTAR offers end-to-end contract research services that combine our technology platform with extensive expertise in phenotypic drug discovery and toxicity evaluation. Our services are designed to accelerate your research and development programs while reducing costs and risks associated with in-house development.
Benefits
• Reduced development timelines through proven methodologies
• Access to specialized expertise and cutting-edge technology
• Cost-effective solutions compared to in-house development
• Regulatory compliance and quality assurance
Available Services
• High-Throughput Screening: Our all-optical platform performs library screening or drug repurposing using various phenotypic and functional assays for different disease modeling, with customization services available to meet your specific needs.
• iPSC Disease Modeling: Comprehensive disease model development and validation using our proprietary iPSC lines. Services include model characterization, biomarker identification, and assay development.
• Cardiotoxicity Testing: Specialized cardiac safety evaluation using human iPSC-derived cardiomyocytes combined with our LumiRDT technology for real-time monitoring of cardiac function and drug-induced toxicity.
• Neurotoxicity Testing: Advanced CNS safety evaluation leveraging human iPSC-derived neuron monocultures or neuron/astrocyte/microglia co-cultures, enabling comprehensive functional assessments of synaptic activity, neuronal viability, and glial responses.
3
Contracted Services
Let Us Do the Heavy Lifting for You
LumiSTAR offers end-to-end contract research services that combine our technology platform with extensive expertise in phenotypic drug discovery and toxicity evaluation. Our services are designed to accelerate your research and development programs while reducing costs and risks associated with in-house development.
Benefits
• Reduced development timelines through proven methodologies
• Access to specialized expertise and cutting-edge technology
• Cost-effective solutions compared to in-house development
• Regulatory compliance and quality assurance
Available Services
• High-Throughput Screening: Our all-optical platform performs library screening or drug repurposing using various phenotypic and functional assays for different disease modeling, with customization services available to meet your specific needs.
• iPSC Disease Modeling: Comprehensive disease model development and validation using our proprietary iPSC lines. Services include model characterization, biomarker identification, and assay development.
• Cardiotoxicity Testing: Specialized cardiac safety evaluation using human iPSC-derived cardiomyocytes combined with our LumiRDT technology for real-time monitoring of cardiac function and drug-induced toxicity.
• Neurotoxicity Testing: Advanced CNS safety evaluation leveraging human iPSC-derived neuron monocultures or neuron/astrocyte/microglia co-cultures, enabling a comprehensive functional assessments of synaptic activity, neuronal viability, and glial responses.
4
Technology Out-Licensing
Fast Track to Global Impact
LumiSTAR's out-licensing program offers access to our proprietary technology through strategic partnerships.
Benefits
• Risk mitigation through proven technology platforms
• Accelerated time-to-market via established protocols
• Access to ongoing R&D works and technical support
Available Assets
• iPSC technology: Access to our iPSC lines, differentiation protocols, disease modeling methods, and automation processes for scalable iPSC production.
• LumiRDT biosensors: Distribution rights to our genetically encoded biosensor portfolio across various regions or sectors.
• Integrated screening platform: Complete technology package including hardware integration, software algorithms, and assay protocols for various phenotypic and functional screening applications.
4
Technology Out-Licensing
Fast Track to Global Impact
LumiSTAR's out-licensing program offers access to our proprietary technology through strategic partnerships.
Benefits
• Risk mitigation through proven technology platforms
• Accelerated time-to-market via established protocols
• Access to ongoing R&D works and technical support
Available Assets
• iPSC technology: Access to our iPSC lines, differentiation protocols, disease modeling methods, and automation processes for scalable iPSC production.
• LumiRDT biosensors: Distribution rights to our genetically encoded biosensor portfolio across various regions or sectors.
• Integrated screening platform: Complete technology package including hardware integration, software algorithms, and assay protocols for various phenotypic and functional screening applications.
4
Technology Out-Licensing
Fast Track to Global Impact
LumiSTAR's out-licensing program offers access to our proprietary technology through strategic partnerships.
Benefits
• Risk mitigation through proven technology platforms
• Accelerated time-to-market via established protocols
• Access to ongoing R&D works and technical support
Available Assets
• iPSC technology: Access to our iPSC lines, differentiation protocols, disease modeling methods, and automation processes for scalable iPSC production.
• LumiRDT biosensors: Distribution rights to our genetically encoded biosensor portfolio across various regions or sectors.
• Integrated screening platform: Complete technology package including hardware integration, software algorithms, and assay protocols for various phenotypic and functional screening applications.
Copyright © 2025 LumiSTAR Biotechnology, Inc. All Rights Reserved
Privacy Policy | Terms & Conditions
Copyright © 2025 LumiSTAR Biotechnology, Inc. All Rights Reserved
Privacy Policy | Terms & Conditions
Copyright © 2025 LumiSTAR Biotechnology, Inc. All Rights Reserved
Privacy Policy | Terms & Conditions